⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL16034467 | 0.97 | NCF1 (0.54) | — | |
| Bromide SCHEMBL16034466 | 0.95 | NCF1 (0.52) | — | |
| SCHEMBL17106592 | 0.86 | — | — | |
| SCHEMBL20604732 | 0.86 | — | — | |
| Bromide SCHEMBL23799915 | 0.84 | — | — | |
| Bromide SCHEMBL20604739 | 0.84 | — | — | |
| SCHEMBL9891009 | 0.79 | NCF1 (0.52) | — | |
| SCHEMBL24319800 | 0.77 | NCF1 (0.62) | — | |
| SCHEMBL757866 | 0.77 | NCF1 (0.62) | — | |
| SCHEMBL28720298 | 0.75 | NCF1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719391-A2 | TRIPLE KINASE INHIBITORS | Unogen Biotech Ltd. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2024249831-A2 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2024-05-16 | — | — | US | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-114213688-B | Polybenzimidazole type amphoteric ion exchange membrane material and preparation method and application thereof | 河北科技大学 | 2022-10-14 | — | — | CN | disclosed |
| CN-114213688-A | Polybenzimidazole type amphoteric ion exchange membrane material and preparation method and application thereof | 河北科技大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-111712490-A | Amino-substituted pyridone derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2020-09-25 | — | — | CN | disclosed |
| US-20200276206-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3684767-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019058393-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-03-28 | — | — | WO | disclosed |
| CN-107922415-A | Novel bicyclic compounds as dual ATX/CA inhibitors | 豪夫迈·罗氏有限公司 | 2018-04-17 | — | — | CN | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |